What is the history of Charcot-Marie-Tooth Disease?

Charcot-Marie-Tooth disease (CMT) was first described in 1886 by three physicians—Jean-Martin Charcot, Pierre Marie, and Howard Henry Tooth—who independently identified this progressive hereditary motor and sensory neuropathy. Since its discovery, our understanding has evolved from viewing it as a single disorder to recognizing it as a genetically diverse group of conditions caused by mutations in over 100 different genes.

How was Charcot-Marie-Tooth disease first identified?

In 1886, the medical landscape was forever changed when Jean-Martin Charcot and his student Pierre Marie in Paris, along with Howard Henry Tooth in London, published their groundbreaking observations. They described a group of patients presenting with progressive muscle weakness and atrophy, predominantly affecting the lower legs and feet, which led to the characteristic "stork leg" appearance and foot drop. At the time, they classified Charcot-Marie-Tooth disease as a "peroneal muscular atrophy," noting that it was a chronic condition that often ran in families, though the underlying genetic mechanisms remained a complete mystery to 19th-century science.

How has our understanding of Charcot-Marie-Tooth disease evolved?

For nearly a century, Charcot-Marie-Tooth disease was diagnosed primarily through clinical examination and electrodiagnostic testing, such as nerve conduction studies. A major turning point occurred in the 1990s with the advent of molecular genetics. Researchers discovered that a duplication on chromosome 17p11.2, involving the PMP22 gene, was responsible for the most common form of the condition (CMT1A). This transition from clinical observation to genetic sequencing allowed for precise classification, moving away from a "one-size-fits-all" diagnosis to a nuanced understanding of various subtypes (CMT1, CMT2, CMT4, and intermediate forms).

What are the major milestones in the history of the condition?

The journey of Charcot-Marie-Tooth disease has been marked by significant shifts in how we approach care and research:

• 1886: The initial clinical description by Charcot, Marie, and Tooth.


• 1950s-1970s: The development of advanced nerve conduction velocity (NCV) testing, which allowed doctors to distinguish between demyelinating (CMT1) and axonal (CMT2) forms.


• 1991: The identification of the PMP22 duplication, marking the birth of modern genetic diagnosis for Charcot-Marie-Tooth disease.


• 2000s-Present: The rise of patient-led organizations like the Charcot-Marie-Tooth Association (CMTA) and the Hereditary Neuropathy Foundation, which have been instrumental in funding research and connecting the 1,193 members of the DiseaseMaps.org community and beyond.

How have misconceptions about the disease been corrected?

Historically, patients with Charcot-Marie-Tooth disease were often misdiagnosed with various forms of muscular dystrophy or spinal cord injuries. Because the condition affects the peripheral nervous system rather than the central nervous system or the muscles themselves, early treatments were often ineffective. Today, we understand that Charcot-Marie-Tooth disease is a peripheral neuropathy that requires a multidisciplinary approach focusing on orthotics, physical therapy, and pain management rather than trying to "fix" the muscles directly. By correcting these misconceptions, the medical community has shifted the focus toward improving quality of life and mobility.

Next steps

• Consult a neurologist or a clinical neurophysiologist to discuss genetic testing if you suspect you have Charcot-Marie-Tooth disease.


• Work with a podiatrist and an orthotist to manage foot drop and gait issues, which are common manifestations of the condition.


• Join a supportive patient community, such as the 1,193 members on DiseaseMaps.org, to share experiences and stay updated on clinical trial opportunities.


• Engage with specialized foundations that fund research into potential gene therapies and neuroprotective medications.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician regarding any medical condition.

References

• National Institute of Neurological Disorders and Stroke (NINDS) - Charcot-Marie-Tooth Disease Information Page.


• Orphanet: A reference portal for information on rare diseases and orphan drugs.


• Online Mendelian Inheritance in Man (OMIM): Comprehensive database of human genes and genetic disorders.


• Charcot-Marie-Tooth Association (CMTA): Patient-focused research and support resources.